App-Quantinova.ai

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Ri Liesner - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

simoctocog alfa

On-Demand Treatment of Bleeding Episodes in Patients with Hereditary Factor X Deficiency Using a High-Purity Factor X Concentrate: Data from 2 Clinical Trials and a Data-Collection Study

James N. Huang - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Factor X deficiency

N/A

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Margaret Ragni - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Luciano Baronciani - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Bay 94-9027 Can be Accurately Measured across Regions with Appropriate One-Stage Assay Reagent Use

Rajiv K. Pruthi - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Antihemophilic factor

The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

Margaret V. Ragni - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Hemostatic Solution

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Augusto B Federici - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

rFVIIa

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Alberto Tosetto - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastrointestinal bleeding

FVIII

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Marijke Van den Berg - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

The Isotype of Antiphospholipid Antibodies and Their Associated Risk on Thrombosis and Pregnancy Morbidity; What Are the Odds?

Walid Chayou - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Carbenoxolone sodium

Recurrent Stroke: The Role of Thrombophilia in a Large International Pediatric Stroke Population

Gabrielle Deveber - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Stroke

N/A

Efficacy and Safety of Prothrombin Complex Concentrate in Patients Treated with Rivaroxaban or Apixaban Compared to Warfarin Presenting with Major Bleeding

Deepa Jayakody Arachchillage - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Prothrombin complex

Fibrinogen Concentrate Vs Cryoprecipitate in Pseudomyxoma Peritonei Surgery: Interim Results from a Prospective, Randomized, Controlled Phase 2 Study

Ashok Roy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gelatinous peritoneal

Fibrinogen (IV)

FCGR2B B2.4 Haplotype Predicts Increased Risk of Red Blood Cell Alloimmunization in Sickle Cell Disease Patients

Abel Costa Neto - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Bitter Taste Receptors System Is Expressed and Functional in Both HSCs and Leukemic Cells

Valentina Salvestrini - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cytarabine liposomal

The Lysine Acetyltransferase Tip60 Is Required for Hematopoietic Stem Cell Maintenance

Akihiko Numata - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Afimoxifene

Definitive EMP and Pre-HSC Emerge in Myb-Null Murine Embryos and Retain Macrophage Potential

Kathleen E. McGrath - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Spastic ataxia Charlevoix-Saguenay type

N/A

Single Cell RNASeq Demonstrates That Mouse Erythroid Cells Are the Last Lineage to Emerge

Elisabeth F Heuston - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Richard Dillon - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute promyelocytic leukemia

arsenic

RNA-Seq Analysis of Clonal Hematopoiesis (CHIP) Blood Leukocytes Shows Dysregulation of Neutrophil / Innate Immunity-Related Genes

Elina K Cook - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

Filters

45280 Abstracts